Should end in Green unless to press down on purpose !

As the glove counters just now lead by this Puma, i believe coming result will be very very good for Super! ( Note: Harta is expected to announce the Q report by this week too )

Another nasi lemak top up for me !

Wow, may be Super result is coming !

Buy some for trading just for nasi lemak, hope the result will out very soon.

Base on profit achieved by Careplus, i believe this Puma can exceed my estimation of Q1'21:600~750M ! Hope to Q report can be announced by end of 27th Oct !

Just assume 600M profit for coming 4 quarters (discount for ASP go down on Q3'21 & rule out extra prod line contribution in Q2'21 financial year of SP):
600M per Q = RM0.215 earning per share
Asume PE=15 ( discount for any uncertainty due to vaccine and demand after 2022 ; any any )
Fair Estimated Price per share = RM0.215 x 4 x 15 = RM12.9 !

Stock: [SUPERMX]: SUPERMAX CORP BHD
Sep 28, 2020 10:57 AM | Report Abuse
The coming Q result (Q1'21; closing by end of this month) which will be announced early of Nov will be another record high! as the spot orders ( about 30% ) were fully booked until 1st haif of next year, the 2021 financial year be a record performance for SuperMax ( my estimation net profit are Q1'21: 600~750M; Q2'21:800M~1.0B; Q3'21: 800M~1B; Q4'21: 750M~`900M

The main focus for coming Q result:
- The increase of revenue /orders visibility and growth
- The profit growth compared with previous Q and projection of coming Q
- Orderbook visibility and prepayment received
- Sustainability of ASP
- The rise of raw material prices (esp : nitrile butadiene)
- Organic growth (additional capacity from new setup lines / other healthcare business..)
- Special bonus or dividend

From CSGCIMB : SuperMax - Glove demand: No signs of slowing down
■ Our recent meeting with SUCB yielded a positive surprise for earnings
prospects, driven by better ASPs and orderbook visibility until end-CY21.
■ SUCB said it has strong order visibility up to end-CY21, with large-volume
buyers willing to pay deposits of 30-50% to lock in orders.
■ Reiterate Add with a lower TP of RM13.20 as we roll-over our valuation year.
Order visibility extended to end-CY21F
Owing to the recent sharp rise in Covid-19 cases globally, Supermax (SUCB) has
continued to see strong global demand for rubber gloves, resulting in its current
orderbook visibility extending to end-CY21F (1HFY6/22F) from end-1H21F (4QFY6/21F).
We understand that large volume buyers (including government and non-government
organisations) are willing to pay deposits of 30-50% in a bid to secure their orders.
Further ASP increases on the cards
While SUCB’s average selling prices (ASPs) are estimated to have risen >200% YTD,
SUCB now expects its ASPs to continue to rise until at least 1QCY21F (we previously
estimated ASPs would rise to end-CY20F). This is given: i) higher usage in both medical
and non-medical sectors; ii) recent rise in nitrile butadiene raw material prices (>40%
YTD); and iii) stocking-up activities by customers due to concerns of supply shortage.
Given that SUCB’s current ASPs are ahead of its peers in the glove sector, we expect
SUCB to record slower ASP growth on a mom basis due to high base effect.
Growing its capacity to capture strong global glove demand
SUCB expects the first four lines of Block B (total 8 lines; 2.2bn pieces p.a.) of Plant 12 to
begin production at end-Oct 20, followed by another four lines by end-Dec 20. Also,
SUCB is building five new plants (Plants 13, 14, 15, 16, 17, with a total capacity of 22.2bn
pieces p.a.). We estimate that the new capacity from these plants will gradually be
phased in from 2HCY21F (1QFY6/22F) onwards up to end-CY22F (end-1HFY6/23F).
This will raise total production capacity by 101% to 48.4bn pieces p.a. by end-CY22F
(from 24bn now).
Expecting another record quarter in 1QFY6/21F
SUCB is likely to announce its 1QFY6/21F results by end-Oct 20. We expect a stronger
net profit on a qoq and yoy basis, marking another new quarterly high. This is due to: a)
higher glove sales volume, b) higher ASPs (>20% qoq) and c) better economies of scale.
Reiterate Add with a lower TP of RM13.20
We lift our FY21-23F EPS by 10.1-72.6% as we pencil in strong glove sales and higher
ASPs (Fig 14). We keep our Add call but with a lower TP of RM13.2, based on 18.3x
CY22 P/E (+0.5 s.d of its 5-year mean) as we roll over our valuation year to CY22. The
TP decline is due to a yoy earnings decline in CY22F as we expect ASP to peak in
CY21F. Still, we like SUCB for its stronger earnings prospects from current strong global
glove demand and its OBM business model which garner better margins vs. its peers.

Time to get some nasi lemak as RM10.00 should be a very strong resistant + the Q result is just around the corner.

Look like the suite rooms for 12x floor was fully booked, 11x floor is still hot ?

The gloves business will be good until 2022..
https://www.theguardian.com/world/2020/oct/15/global-covid-report-young-and-healthy-may-not-get-vaccine-until-2022-who-says

Great to see above RM5.00 then RM6.00 is the target ?

RM5.00 is strong resistant or road block for CF to advance further.

Few attempt to challenge RM4.80 but still GG..

TopGlove to overtake TiGer is just matter of time...

Most anticipated things from this Puma :
- Coming Q1'21 quarter result ( by this coming 2 weeks )
- List under KLCI Index ( announce on 3rd Dec and list on 21st Dec
- Special dividend or bonus

Hope CF will start to perform better after some washout for previous gain..

My nasi lemak is coming......

Hope to cross over RM4.80 and challenge the RM5 again........

https://www.dol.gov/sites/dolgov/files/ILAB/child_labor_reports/tda2019/2020_TVPRA_List_Online_Final.pdf

This news was released end of last month. Look at the report, the ban also included electronics. Are those involved in the electronics industries ( MPI / Unisem / Inari / KESM / Gtronics / ... many EMS companies ) affected ??

I think i can get my nasi lemak this afternoon or tomorrow morning.

Believe in their coming solid quarter result (This is a rare case for a company that can tell your in back and white of their booking orders, down payment received for their orders and telling in advance of the asp will be better. Pls refer to their Q420'quarter report ) !
So why worry as this is very healthy washout to build a solid base for further advancement !

Wow ! Another washout for this Puma. But i'm still hold tight tight for coming quarter result.

Sustain firmly above RM4.80 will enable CF to challenge and advance to RM5+

As the Q1'21 Quarter result will be annouced next week, then crossing of RM12+ (previous peak is RM12.22 ) by end of this month is possible as the estimated profit will be another record high ( the higher should be Q2'21 base on prospect information from Q4'20 Q resport ).
Factors to support with no guessing:
- Very good business visibility ( booking orders and actual down payments stated in Q4'20 report)
- Net cash and cash rich company
- Strong growth at least for coming few quarters
- Business expansion ( additional production lines and Face Mask business )

If Mahsing can become a major shareholder, then it is really a good news as previous major shareholder was disposed all his shares few weeks ago. This will lead CF to new direction.

It is a good try to challenge RM4.80, hope tomorrow will cross over RM5.00

Better hold tight tight as 1 more week the Q result be announced

Last push to challenge and cross over RM4.80 ?

Will this Puma will challenge RM11.00 within this week ; time will tell. I believe to reach RM12+ when the Q result is out !

If able to sustain above RM4.80 then RM5.00 is not a dream within this week.

Will challenge RM4.80 very soon

Wall Street saw some signs that the U.S. pharmaceutical industry was facing challenges in its pursuit of a remedy for COVID-19, which has infected more than 37 million people globally so far, according to data aggregated by Johns Hopkins University.
Pharmaceutical giant Johnson & Johnson JNJ announced a pause of all of its COVID-19 vaccine trials. And a clinical trial for a coronavirus antibody treatment made by Eli Lilly LLY was paused because of a “potential safety concern.”
https://www.marketwatch.com/story/dow-futures-slip-as-earnings-season-kicks-off-j-j-pauses-coronavirus-vaccine-trial-11602589284?mod=mw_quote_news

Not a good news for vaccine...
https://www.ft.com/content/6ea4c5e4-abc8-4b7a-8fe2-64ad22ea3978

Breaking strong resistant level of RM4.20 means this CF will advance to higher ( 1st may be RM4.60 then challenge RM5.XX )

Breaking the RM9.00 (strong resistant level) will put TG the right path to advance to next new high for coming days !

The only setbacks are : issued too many warrants and its major shareholder sell off his shares

Base on 5 year records, the fundamental of CF is still the best among the 2nd tiers

Will Comfort catch up its price as this counter is really behind compared with others ?

This Puma should able to challenge RM12 within a month time.

Hope TG can stay above RM9.00 ( a very strong resistant ) firmly so that can path it way to new high !

Following catalysts will push this Puma to another new peak in Nov :
- Coming 21'Q1 outstanding profit
- Potential include in KLCI Index (big foreign/local fund buying list )

Today the foreign funds are the sole buyer (127M ) while local IBs are net sell of 119M and local retailers are also net sell of 8M

Will this Puma will crossing RM9.80 and challenge RM10.00 within this week for 2nd x ?

Compare with other 2nd tier glove maker, this CF is still behind. May provide oppotunity..

Today not nasi lemak but a nice dinner !

Still the same word. Hold tight tight for existing share and just play a daily trading when any washout/sudden drop ! Hopefully another nasi lemak for today !

This coming 24hrs will see how effective of the contra players are "washout" by today morning session

A few washouts are expected before move to next level. Hold tight tight until the coming quarter result ( est at least RM600M~750M )